Gene preparations
View Patent ↗The present invention relates to gene preparations comprising desired genes or vectors containing desired genes integrated there into and carriers for supporting the same. The carrier is preferably a soluble collagen such as atelocollagen and may further include an additive. The invention also encompasses methods for delivering genes to cells employing the gene preparation.
1. A method for delivering a gene for uptake by a cell of a subject, comprising administering subcutaneously, intramuscularly, or intraperitoneally a sustained release gene preparation comprising atelocollagen and an intended gene or a vector comprising said intended gene, wherein said atelocollagen is present in the amount of 0.01–25 w/w % of the preparation, wherein said gene is thereby taken up by said cell of said subject.
2. The method according to claim 1 , wherein the atelocollagen is present in the amount of 0.05–10 w/w % of the preparation.
3. The method according to claim 2 , wherein the atelocollagen is present in the amount of 0.05–5 w/w % of the preparation.
4. The method according to any one of claims 1 – 3 wherein the preparation further comprises an additive.
5. The method according to claim 4 , wherein the atelocollagen is present in the amount of 2 w/w % or more of the preparation, and the additive is present in the amount of 5–900 w/w % of the atelocollagen.
6. The method according to any one of claims 1 – 3 , wherein the preparation is in a gel form.
7. A method for delivering a gene for uptake by a cell of a subject, comprising administering subcutaneously, intramuscularly, or intraperitoneally a controlled release gene preparation comprising atelocollagen, an additive and an intended gene or a vector comprising said intended gene, wherein said atelocollagen is present in an amount of 0.01–25 w/w % of the preparation, wherein said gene is thereby taken up by said cell of said subject.
8. A method for delivering a gene for uptake by a cell of a subject, comprising administering subcutaneously, intramuscularly, or intraperitoneally a sustained release gene preparation obtained by drying a gel comprising 0.2–30 w/w % of atelocollagen, and an intended gene or a vector comprising said intended gene, wherein said gene is thereby taken up by said cell of said subject.
9. The method according to claim 8 , wherein the atelocollagen is 0.3–5 w/w % in the gel.
10. The method according to claim 9 , wherein the atelocollagen is 0.4–2 w/w % in the gel.
11. The method according to any one of claims 8 – 10 , wherein the gel further comprises an additive.
12. The method according to claim 11 , wherein the atelocollagen is 1% or more in the gel, and the additive is 5–900 w/w % of the atelocollagen.
13. The method according to any one of claims 8 – 10 , wherein the preparation is in a form of a film.
14. A method for delivering a gene for uptake by a cell of a subject, comprising administering subcutaneously, intramuscularly, or intraperitoneally a controlled release gene preparation obtained by drying a gel comprising 0.2–30 w/w % of atelocollagen, an additive, and an intended gene or a vector comprising said intended gene, wherein said gene is thereby taken up by said cell of said subject.
15. A method for delivering a gene for uptake by a cell of a subject, comprising administering subcutaneously, intramuscularly, or intraperitoneally a sustained release gene preparation obtained by drying a gel comprising 10–30 w/w % of atelocollagen, and an intended gene or a vector comprising said intended gene, wherein said gene is thereby taken up by said cell of said subject.
16. The method according to claim 15 , wherein the gel further comprises an additive.
17. The method according to claim 16 , wherein the additive is present in the amount of 5–100 w/w % of the atelocollagen.
18. The method according to any one of claims 15 – 17 , wherein the preparation is in a rod form.
19. A method for delivering a gene for uptake by a cell of a subject, comprising administering to said subject a sustained release gene preparation obtained by the process comprising:
obtaining a sponge by lyophilizing a gel comprising 0.05 to 5 w/w % of atelocollagen, and an intended gene or a vector comprising said intended gene;
obtaining a gel in which the concentration of atelocollagen is 10 to 30 w/w % by adding distilled water to the sponge;
forming a rod by squeeze molding the gel; and
drying,
wherein the gene preparation is administered subcutaneously, intramuscularly, or intraperitoneally.